Avalyn Pharma Inc. AVLN
26.81 USD +1.21 (+4.73%)
At closeNov 3, 2026, 4:10 PM EST
26.81 0.00 0.00%
After hours · Nov 3, 4:10 PM ET
25.45 Day range 26.96
22.24 52-week range 40.17
- YTD
- -9.09%
- 1 year
- -9.09%
- Market cap
- 1.19B
- EPS (ttm)
- -2.47
- Shares out
- 44.33M
- Forward P/E
- -10.39
- YTD return
- -9.09%
- 1-year return
- -9.09%
- Volume
- 450.17K
- Avg volume
- 289.84K
- Open
- 25.87
- Previous close
- 25.60
- Day's range
- 25.45 – 26.96
- 52-week range
- 22.24 – 40.17
- Price target
- 61.80 (+130.5%)
- Earnings date
- Nov 11, 2026
2Y -2.72 (-9.22%)
Key statistics
- Enterprise value
- 799.61M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.98
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 352.42M
- Total debt
- 17.11M
- Return on equity
- 0.00%
- Short % of float
- 5.31%
- 50-day average
- 29.90
- 200-day average
- 29.96
Analyst view
Price target (mean) 61.80 +130.5% upside
Now 26.81
- Target (low)
- 52.00
- Target (mean)
- 61.80
- Target (high)
- 80.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.75.
Financials — quick view
AVLN Revenue — quarterly 0
AVLN Net income — quarterly -28.93M
AVLN EPS — quarterly -0.98
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.71333 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.77667 | -0.98 | -0.20 | -26.18% |
| Jun 3, 2026 | Mar 31, 2026 | -5.98 | -21.83 | -15.85 | -265.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Raymond James | init | — | Outperform |
| Aug 13, 2026 | Morgan Stanley | main | Overweight | Overweight |
| May 26, 2026 | Evercore ISI Group | init | — | Outperform |
| May 26, 2026 | Guggenheim | init | — | Buy |
| May 26, 2026 | Morgan Stanley | init | — | Overweight |
About Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- avalynpharma.com
News
Avalyn to Present at Upcoming Investor Conferences 
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday 
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60 
Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated “Moderate Buy” by Wall Street Analysts 
Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach 
Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile 
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors 
Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript - Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Your note
Sign in to keep a note on AVLN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARROLL JILL | Director | Purchase | Apr 30, 2026 | 0 |
| FMR LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 30, 2026 | 0 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 30, 2026 | 3,883,290 |
| SR ONE CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 30, 2026 | 0 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 30, 2026 | 1,275,490 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.16% | 5,835,259 | 156.44M | Jun 29, 2026 |
| Novo Holdings A/S | 8.76% | 3,883,289 | 104.11M | Jun 29, 2026 |
| SR One Capital Management, LP | 7.46% | 3,308,649 | 88.70M | Jun 29, 2026 |
| Perceptive Advisors Llc | 6.03% | 2,675,296 | 71.72M | Jun 29, 2026 |
| Montanova Capital LLC | 5.65% | 2,503,109 | 67.11M | Jun 29, 2026 |
| NVP Associates, LLC | 5.12% | 2,268,404 | 60.82M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.78% | 1,231,620 | 33.02M | Jul 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 1.41% | 627,190 | 16.81M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.21% | 534,440 | 14.33M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.05% | 466,565 | 12.51M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.94% | 415,610 | 11.14M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.89% | 396,069 | 10.62M | Jun 29, 2026 |